Home > DNA/RNA Synthesis & > Hydroxyurea

Hydroxyurea

羟基脲,nci-c04831,nsc32065,Hydroxycarbamide,Cytodrox,Hydrea,Biosupressin

Hydroxyurea具有抗肿瘤活性，能通过抑制核苷二磷酸还原酶来阻断DNA合成。

目录号
EY1379
EY1379
纯度
99.19%
99.19%
规格
100 mg
500 mg
原价
200
300
售价
200
300
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Hydroxyurea is an antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Davies, B.W., et al. 2009. Mol. Cell. 36: 845-860.
    [2] Lu, X., et al. 2010. Cancer Sci. 101: 609-615.
    [3] Hendricks, S.P. and Mathews, C.K. 1998. J. Biol. Chem. 273: 29519-29523.

    分子式
    CH4N2O2    		 分子量
    76.05    		 CAS号
    127-07-1    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    20 mg/mL    		 Water
    20 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02675790 Sickle Cell Disease|Sickle Cell Anemia|Stroke Drug: Moderate Dose Hydroxyurea|Drug: Low Dose Hydroxyurea Vanderbilt University|Aminu Kano Teaching Hospital|Murtala Muhammed Specialist Hospital Phase 3 2016-12-01 2016-11-02
    NCT01966731 Sickle Cell Disease Drug: Hydroxyurea Children's Hospital Medical Center, Cincinnati|Bristol-Myers Squibb Phase 1|Phase 2 2014-06-01 2016-08-31
    NCT01506544 Sickle Cell Anemia Drug: Hydroxyurea Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1 2011-12-01 2014-12-10
    NCT00613054 Glioblastoma|Gliosarcoma Drug: Zactima, Gleevec, Hydroxyurea Annick Desjardins|Novartis Pharmaceuticals|AstraZeneca|Duke University Phase 1 2007-11-01 2012-12-04
    NCT01389024 Sickle Cell Disease|Stroke Drug: Hydroxyurea|Drug: Placebo Johns Hopkins University|National Center for Research Resources (NCRR)|Washington University School of Medicine|Vanderbilt University School of Medicine|University of Alabama at Birmingham|Children's Hospital of Philadelphia|Medical University of South Carolina|RTI International|Columbia University|Mercy Children's Hospital|Sinai Hospital of Baltimore Phase 2 2011-10-01 2016-09-03
    NCT00613132 Glioblastoma|Gliosarcoma Drug: Gleevec, RAD001, and Hydroxyurea Annick Desjardins|Novartis Pharmaceuticals|Duke University Phase 1 2005-05-01 2013-02-19
    NCT01801423 Sickle Cell Anemia|Sickle Cell Disease|Stroke Drug: Hydroxyurea Vanderbilt University Medical Center|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Aminu Kano Teaching Hospital 2013-02-01 2017-03-20
    NCT01624038 Thalassemia Intermedia Drug: Hydroxyurea ,Epiao|Drug: hydroxyurea, blood transfusion Ain Shams University Phase 2|Phase 3 2012-06-01 2012-06-18
    NCT00354913 Glioblastoma|Gliosarcoma Drug: hydroxyurea|Drug: imatinib mesylate Duke University|National Cancer Institute (NCI)|Novartis Pharmaceuticals Phase 2 2005-05-01 2013-01-14
    NCT00928707 Polycythemia Vera Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea Italfarmaco Phase 2 2009-06-01 2012-09-17
    NCT00784082 Sickle Cell Disease Drug: Hydroxycarbamide, Hydroxyurea (drug) Assistance Publique - H么pitaux de Paris 2009-05-01 2013-01-30
    NCT01521299 Advanced Solid Tumors Drug: Hydroxyurea Dartmouth-Hitchcock Medical Center Phase 1 2012-03-01 2012-08-24
    NCT00615927 Glioblastoma|Gliosarcoma Drug: Imatinib Mesylate & Hydroxyurea Duke University|Novartis Pharmaceuticals Phase 2 2006-02-01 2013-03-13
    NCT01848925 Sickle Cell Disease Biological: SANGUINATE鈩Drug: Hydroxyurea Prolong Pharmaceuticals Phase 1 2013-05-01 2014-12-02
    NCT00519701 Sickle Cell Anemia Drug: hydroxyurea Duke University 2002-04-01 2007-08-22
    NCT00387933 Brain and Central Nervous System Tumors Drug: hydroxyurea|Drug: imatinib mesylate|Drug: vatalanib Duke University|National Cancer Institute (NCI) Phase 1 2005-07-01 2015-10-11
    NCT01976416 Sickle Cell Anemia|Sickle Cell Disease|Malaria Drug: Hydroxyurea|Drug: Placebo Indiana University|Doris Duke Charitable Foundation|Makerere University|Mulago Hospital, Uganda|Children's Hospital Medical Center, Cincinnati Phase 3 2014-09-01 2017-03-22
    NCT00154375 Glioblastoma Multiforme|Astrocytoma Drug: Imatinib mesylate|Drug: Hydroxyurea Novartis Pharmaceuticals|Novartis Phase 3 2004-10-01 2011-04-19
    NCT01950585 Pulmonary Hypertension Drug: Hydroxyurea National Heart, Lung, and Blood Institute (NHLBI)|The Cleveland Clinic|National Institutes of Health Clinical Center (CC) Early Phase 1 2013-09-06 2017-01-24
    NCT03020615 Sickle Cell Anemia Drug: Hydroxyurea St. Jude Children's Research Hospital|National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2017-03-31 2017-03-01

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：